|
| Galectin1 as an oncotarget in gliomas and melanomas |
|
https://doi.org/10.18632/oncotarget.408
Florence Lefranc, Véronique Mathieu, and Robert Kiss
|
| 892-893 |
|
| Resistance to EGFR inhibitors: Molecular determinants and the enigma of head and neck cancer |
|
https://doi.org/10.18632/oncotarget.407
Luc G.T. Morris, and Timothy A. Chan
|
| 894-895 |
|
| Metformin: Multifaceted protection against cancer |
|
https://doi.org/10.18632/oncotarget.387
Sonia Del Barco, Alejandro Vazquez-Martin, SÃlvia CufÃ, Cristina Oliveras-Ferraros, Joaquim Bosch-Barrera, Jorge Joven, Begoña Martin-Castillo, and Javier A Menendez
|
| 896-917 |
|
| AHI1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders |
|
https://doi.org/10.18632/oncotarget.405
Sharmin Esmailzadeh, and Xiaoyan Jiang
|
| 918-934 |
|
| Mitotic centromereassociated kinesin MCAK: a potential cancer drug target |
|
https://doi.org/10.18632/oncotarget.416
Mourad Sanhaji, Claire T Friel, Linda Wordeman, Frank Louwen, and Juping Yuan
|
| 935-947 |
|
| Regulation of glucose metabolism by p53: Emerging new roles for the tumor suppressor |
|
https://doi.org/10.18632/oncotarget.389
Esha Madan, Rajan Gogna, Madan Bhatt, Uttam Pati, Periannan Kuppusamy, and Abbas Ali Mahdi
|
| 948-957 |
|
| Mechanism of Activation of AMPK and Upregulation of OGG1 by Rapamycin in Cancer Cells |
|
https://doi.org/10.18632/oncotarget.381
Samy L. Habib
|
| 958-959 |
|
| Pilot study of a pediatric metronomic 4drug regimen |
|
https://doi.org/10.18632/oncotarget.358
Nicolas André, Sylvie Abed, Daniel Orbach, Corinne Armari Alla, Laetitia Padovani, Eddy Pasquier, Jean Claude Gentet, and Arnauld Verschuur
|
| 960-965 |
|
| MED12 exon 2 mutations are common in uterine leiomyomas from South African patients |
|
https://doi.org/10.18632/oncotarget.370
Netta Mäkinen, Hanna-Riikka Heinonen, Shane Moore, Ian Tomlinson, Zephne van der Spuy, and Lauri Aaltonen
|
| 966-969 |
|
| CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients |
|
https://doi.org/10.18632/oncotarget.398
Daniel Baumhoer, Mareike Elsner, Jan Smida, Stephanie Zillmer, Sandra Rauser, Cédrik Schoene, Benjamin Balluff, Stefan Bielack, Gernot Jundt, Axel Walch, and Michaela Nathrath
|
| 970-975 |
|
| Frizzled receptor 6 marks rare highly tumourigenic stemlike cells in mouse and human neuroblastomas |
|
https://doi.org/10.18632/oncotarget.410
Sandra Cantilena, Fabio Pastorino, Olesya Chayka, Annalisa Pezzolo, Vito Pistoia, Mirco Ponzoni, and Arturo Sala
|
| 976-983 |
|
| PARP inhibition sensitizes childhood high grade glioma medulloblastoma and ependymoma to radiation |
|
https://doi.org/10.18632/oncotarget.362
Dannis Gilbert Van Vuurden, Esther Hulleman, Olga L.M. Meijer, Laurine E. Wedekind, Marcel Kool, Hendrik Witt, W. Peter Vandertop, Thomas Würdinger, David P. Noske, Gertjan J.L. Kaspers, and Jacqueline Cloos
|
| 984-996 |
|
| Antitumoral activity of allosteric inhibitors of Protein kinase CK2 |
|
https://doi.org/10.18632/oncotarget.361
Virginie Moucadel, Renaud Prudent, Céline F. Sautel, Florence Teillet, Caroline Barette, Laurence Lafanechere, Veronique Receveur-Brechot, and Claude Cochet
|
| 997-1010 |
|
| Geminin overexpression induces mammary tumors via suppressing cytokinesis |
|
https://doi.org/10.18632/oncotarget.363
Zannel Blanchard, Rohit Malik, Nicole Mullins, Christine Maric, Hugh Luk, David Horio, Brenda Hernandez, Jeffrey Killeen, and Wael M. ElShamy
|
| 1011-1027 |
|
| Cord blood stem cells revert glioma stem cell EMT by down regulating transcriptional activation of Sox2 and Twist1 |
|
https://doi.org/10.18632/oncotarget.367
Kiran Kumar Velpula, Venkata Ramesh Dasari, Andrew J. Tsung, Dzung H. Dinh, and Jasti S. Rao
|
| 1028-1042 |
|
| Putting the brakes on mammary tumorigenesis: Loss of STAT1 predisposes to intraepithelial neoplasias |
|
https://doi.org/10.18632/oncotarget.371
Christine Schneckenleithner, Zsuzsanna Bago-Horvath, Helmuth Dolznig, Nina Neugebauer, Karoline Kollmann, Thomas Kolbe, Thomas Decker, Dontscho Kerjaschki, Kay-Uwe Wagner, Mathias Müller, Dagmar Stoiber, and Veronika Sexl
|
| 1043-1054 |
|
| A Novel Dual Signaling Axis for NSP 5a3a induced apoptosis in Head and Neck Carcinoma |
|
https://doi.org/10.18632/oncotarget.306
Luca D'Agostino, and Antonio Giordano
|
| 1055-1074 |
|
| Annexin A2 is a novel Cellular Redox Regulatory Protein involved in Tumorigenesis |
|
https://doi.org/10.18632/oncotarget.375
Patricia Alexandra Madureira, Richard Hill, Victoria Ann Miller, Carman Giacomantonio, Patrick WK Lee, and David Morton Waisman
|
| 1075-1093 |
|
| DNAPKCS binding to p53 on the p21WAF1/CIP1 promoter blocks transcription resulting in cell death |
|
https://doi.org/10.18632/oncotarget.378
Richard Hill, Patricia A. Madureira, David M. Waisman, and Patrick W.K. Lee
|
| 1094-1108 |
|
| Thyrocytespecific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors |
|
https://doi.org/10.18632/oncotarget.380
Valeria G. Antico Arciuch, Marika A. Russo, Mariavittoria Dima, Kristy S. Kang, Florence Dasrath, Xiao-Hui Liao, Samuel Refetoff, Cristina Montagna, and Antonio Di Cristofano
|
| 1109-1126 |
|
| Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height |
|
https://doi.org/10.18632/oncotarget.385
Katrina Tatton-Brown, Sandra Hanks, Elise Ruark, Anna Zachariou, Silvana Del Vecchio Duarte, Emma Ramsay, Katie Snape, Anne Murray, Elizabeth R. Perdeaux, Sheila Seal, Chey Loveday, Siddharth Banka, Carol Clericuzio, Frances Flinter, Alex Magee, Vivienne McConnell, Michael Patton, Wolfgang Raith, Julia Rankin, Miranda Splitt, Volker Strenger, Clare Taylor, Patricia Wheeler, I. Karen Temple, Trevor Cole, Jenny Douglas, and Nazneen Rahman
|
| 1127-1133 |
|
| PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells |
|
https://doi.org/10.18632/oncotarget.386
Allan Siu, Carl Virtanen, and Jan Jongstra
|
| 1134-1144 |
|
| TAp73alpha protects small cell lung carcinoma cells from caspase2 induced mitochondrial mediated apoptotic cell death |
|
https://doi.org/10.18632/oncotarget.391
Naveen Muppani, Ulrika Nyman, and Bertrand Joseph
|
| 1145-1154 |
|
| Phosphatase inhibitor sodium stibogluconate in combination with interferon IFN alpha 2b: phase I trials to identify pharmacodynamic and clinical effects |
|
https://doi.org/10.18632/oncotarget.563
Taolin Yi, Paul Elson, Masato Mitsuhashi, Barbara Jacobs, Emese Hollovary, G. Thomas Budd, Timothy Spiro, Pierre Triozzi, and Ernest Borden
|
| 1155-1164 |
|
| Overexpression of TWIST2 correlates with poor prognosis in Head and Neck Squamous Cell Carcinomas |
|
https://doi.org/10.18632/oncotarget.390
Daniela Gasparotto, Jerry Polesel, Alessandra Marzotto, Roberta Colladel, Sara Piccinin, Piergiorgio Modena, Alessandra Grizzo, Sandro Sulfaro, Diego Serraino, Luigi Barzan, Claudio Doglioni, and Roberta Maestro
|
| 1165-1175 |
|
| Phospholipase PLA2G7 associated with aggressive prostate cancer promotes prostate cancer cell migration and invasion and is inhibited by statins |
|
https://doi.org/10.18632/oncotarget.397
Paula Vainio, Laura Lehtinen, Tuomas Mirtti, Mika Hilvo, Tuulikki Seppänen-Laakso, Johannes Virtanen, Anna Sankila, Stig Nordling, Johan Lundin, Antti Rannikko, Matej OreÅ¡iÄ, Olli Kallioniemi, and Kristiina Iljin
|
| 1176-1190 |
|
| Genomewide analysis discloses reversal of the hypoxiainduced changes of gene expression in colon cancer cells by zinc supplementation |
|
https://doi.org/10.18632/oncotarget.395
Michal Sheffer, Amos J. Simon, Jasmine Jacob-Hirsch, Gideon Rechavi, Eytan Domany, David Givol, and Gabriella D'Orazi
|
| 1191-1202 |
|
| Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a proinvasive secretome |
|
https://doi.org/10.18632/oncotarget.382
Paul M. Neilsen, Jacqueline E. Noll, Rachel J. Suetani, Renee B Schulz, Fares Al-Ejeh, Andreas Evdokiou, David P. Lane, and David F. Callen
|
| 1203-1217 |
|
| The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA |
|
https://doi.org/10.18632/oncotarget.359
Ming Wang, and Andrei L. Gartel
|
| 1218-1226 |
|
| Characterization of the Human Folate Receptor Alpha Via Novel AntibodyBased Probes |
|
https://doi.org/10.18632/oncotarget.412
Daniel J. O’Shannessy, Elizabeth B. Somers, Earl Albone, Xin Cheng, Young Chul Park, Brian E. Tomkowicz, Yoshitomo Hamuro, Thomas O. Kohl, Tracy M. Forsyth, Robert Smale, Yao-Shi Fu, and Nicholas C. Nicolaides
|
| 1227-1243 |
|
| A Modular Strategy to Prepare Multivalent Inhibitors of ProstateSpecific Membrane Antigen PSMA |
|
https://doi.org/10.18632/oncotarget.415
Sangeeta Ray Banerjee, Mrudula Pullambhatla, Hassan Shallal, Ala Lisok, Ronnie C. Mease, and Martin G. Pomper
|
| 1244-1253 |
|
| Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator pololike kinase PLK1 |
|
https://doi.org/10.18632/oncotarget.406
Nancy Liu-Sullivan, Jianping Zhang, Amy Bakleh, John Marchica, Jinyu Li, Despina Siolas, Sylvie Laquerre, Yan Y. Degenhardt, Richard Wooster, Kenneth Chang, Gregory J. Hannon, and Scott Powers
|
| 1254-1264 |
|
| Identification of a chrXq273 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients |
|
https://doi.org/10.18632/oncotarget.401
Marina Bagnoli, Loris De Cecco, Anna Granata, Roberta Nicoletti, Edoardo Marchesi, Paola Alberti, Barbara Valeri, Massimo Libra, Mattia Barbareschi, Francesco Raspagliesi, Delia Mezzanzanica, and Silvana Canevari
|
| 1265-1278 |
|
| Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein BMAL1 |
|
https://doi.org/10.18632/oncotarget.411
Yan Hu, Mary L. Spengler, Karen K. Kuropatwinski, Maria Comas, Marilyn Jackson, Mikhail V. Chernov, Anatoly S. Gleiberman, Natalia Fedtsova, Youcef M. Rustum, Andrei V. Gudkov, and Marina Antoch
|
| 1279-1290 |
|
| Epigenetic regulation of DeltaLike1 controls Notch1 activation in gastric cancer |
|
https://doi.org/10.18632/oncotarget.414
Giulia Piazzi, Lucia Fini, Michael Selgrad, Melissa Garcia, Yahya Daoud, Thomas Wex, Peter Malfertheiner, Antonio Gasbarrini, Marco Romano, Richard L. Meyer, Robert M Genta, James G. Fox, C. Richard Boland, Franco Bazzoli, and Luigi Ricciardiello
|
| 1291-1301 |
|
| Targeting Autophagy Addiction in Cancer |
|
https://doi.org/10.18632/oncotarget.384
Joseph D. Mancias, and Alec C. Kimmelman
|
| 1302-1306 |
|
| Finding cancer’s weakest link |
|
https://doi.org/10.18632/oncotarget.396
Nicole Michel Sodir, and Gerard I. Evan
|
| 1307-1313 |
|
| Will PI3K pathway inhibitors be effective as single agents in patients with cancer |
|
https://doi.org/10.18632/oncotarget.409
Joan T. Garrett, Anindita Chakrabarty, and Carlos L. Arteaga
|
| 1314-1321 |
|
| AMPK in BCRABL expressing leukemias Regulatory effects and therapeutic implications |
|
https://doi.org/10.18632/oncotarget.413
Leonidas Platanias, and Eliza Vakana
|
| 1322-1328 |
|
| Is human cytomegalovirus a target in cancer therapy |
|
https://doi.org/10.18632/oncotarget.383
John Inge Johnsen, Ninib Baryawno, and Cecilia Söderberg-Nauclér
|
| 1329-1338 |
|
| T cell but not tumor cellproduced TGFβ1 promotes the development of spontaneous mammary cancer |
|
https://doi.org/10.18632/oncotarget.403
Abira Sarkar, Moses K. Donkor, and Ming O. Li
|
| 1339-1351 |
|
| NCI’s provocative questions on cancer: some answers to ignite discussion |
|
https://doi.org/10.18632/oncotarget.432
Mikhail V. Blagosklonny
|
| 1352-1367 |
